Tue11202018

Robins Global News & Noticias



  • Odds: Packers vs. Bears
    Odds: Packers vs. Bears
  • Featured Guest Post
    Featured Guest Post
  • Publicación de invitado destacado
    Publicación de invitado destacado
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

Special News Reports

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting


CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab
Novel adenosine gene signature biomarker associated with response to CPI-444 therapyCPI-006 early clinical data showed evidence of immune activation of B cells and effect on lymphocyte traffickingBURLINGAME, Calif., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced updated clinical and biomarker data from ongoing Phase 1/1b studies of its lead programs, CPI-444 and CPI-006. Updated results from its Phase 1/1b clinical trial of CPI-444 in patients with treatment-refractory renal cell carcinoma (RCC) demonstrated an overall survival (OS) of 88 percent at more than 20 months follow-up with CPI-444 administered in combination with atezolizumab. The clinical data were presented in an oral session at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting in Washington, D.C., by Lawrence Fong, M.D., study investigator and leader of the Cancer Immunotherapy Program at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.Additionally, CPI-444 biomarker data from the Phase 1/1b study showing that expression of a novel adenosine gene signature was significantly associated with tumor regression were presented both in the oral presentation and in a poster session at the SITC meeting. Early clinical data from an ongoing Phase 1/1b study evaluating CPI-006 as a monotherapy showing evidence of immune activation of B cells were presented in a poster session.CPI-444, Corvus’ lead product candidate, is a selective and potent inhibitor of the adenosine A2A receptor. It is currently being evaluated in Phase 1/1b and 1b/2 clinical trials in patients with various solid tumors as a monotherapy and in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody. CPI-006 is a humanized monoclonal antibody directed against CD73. It is currently being evaluated in a Phase 1/1b three-arm clinical trial in patients with a variety of solid tumors as a monotherapy, in combination with CPI-444, and in combination with pembrolizumab, an anti-PD-1 antibody.“The newest data on our two lead programs further establish a promising foundation for the application of adenosine blockade in cancer therapy,” said Richard A. Miller, M.D., an on...


Posted: 2018-11-10 22:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.






Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting | Special News Reports - Newscast






Related Bing Web Search

  • No items found
  • Related News Story Videos From Youtube

  • Sorry No Video Items Found




  • Blow Us A Whistle

    Comments (Whistles) Designed By Disqus




    Company Information

    Official Content Providers











    PRIVACY POLICY

    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2018 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.